Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.42 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.42 |
| ▸ | PKN2 | Q16513 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4775551 | 0.99 | RAB9A (0.45) | RAB9ANPC1MAPK1TP53KDM4E | |
| SCHEMBL4768918 | 0.96 | RAB9A (0.46) | RAB9ANPC1MAPK1TP53KDM4E | |
| Hydrochloric Acid SCHEMBL4774080 | 0.95 | RAB9A (0.46) | RAB9ANPC1MAPK1TP53KDM4E | |
| SCHEMBL4772825 | 0.93 | RAB9A (0.45) | RAB9ANPC1MAPK1TP53KDM4E | |
| SCHEMBL4774659 | 0.92 | NPC1 (0.49) | RAB9ANPC1TP53MAPT | |
| Hydrochloric Acid SCHEMBL4773346 | 0.92 | RAB9A (0.45) | RAB9ANPC1MAPK1TP53KDM4E | |
| Hydrochloric Acid SCHEMBL6726667 | 0.92 | RAB9A (0.45) | RAB9ANPC1MAPK1TP53KDM4E | |
| SCHEMBL14102662 | 0.92 | KMT2A (0.44) | RAB9ANPC1KDM4EALDH1A1HPGD | |
| Hydrochloric Acid SCHEMBL4764283 | 0.91 | NPC1 (0.48) | RAB9ANPC1TP53MAPT | |
| SCHEMBL4771543 | 0.91 | RAB9A (0.45) | RAB9ANPC1MAPK1TP53KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7541371-B2 | Method for treating a motor neuron disease | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-06-02 | — | — | US | claimed |
| US-20080027039-A1 | Method for treating a motor neuron disease | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2008-01-31 | — | — | US | claimed |
| US-6790844-B2 | MUSCLE RELAXANTS; ANTISEROTONINE AGENT | EISAI CO., LTD (JP) | 2004-09-14 | — | — | US | claimed |
| US-20020013460-A1 | Condensed pyridine compound | EISAI CO., LTD | 2002-01-31 | — | — | US | claimed |
| EP-1123702-A1 | ANALGESICS | Eisai Co., Ltd. (JP) | 2001-08-16 | — | — | EP | claimed |
| EP-1020445-A1 | FUSED PYRIDINE DERIVATIVES | Eisai Co., Ltd. (JP) | 2000-07-19 | — | — | EP | claimed |
| US-7541371-B2 | Method for treating a motor neuron disease | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-06-02 | — | — | US | disclosed |
| US-7541371-B2 | Method for treating a motor neuron disease | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-06-02 | — | — | US | disclosed |
| US-7541371-B2 | Method for treating a motor neuron disease | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-06-02 | — | — | US | disclosed |
| EP-1020445-B1 | FUSED PYRIDINE DERIVATIVES | EISAI R&D MAN CO LTD (JP) | 2008-08-13 | — | — | EP | disclosed |
| EP-1020445-B1 | FUSED PYRIDINE DERIVATIVES | EISAI R&D MAN CO LTD (JP) | 2008-08-13 | — | — | EP | disclosed |
| US-20080027039-A1 | Method for treating a motor neuron disease | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2008-01-31 | — | — | US | disclosed |
| US-20080027039-A1 | Method for treating a motor neuron disease | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2008-01-31 | — | — | US | disclosed |
| US-6875761-B2 | Certain 1,3-disubstituted isoquinoline derivatives | EISAI CO., LTD. (JP) | 2005-04-05 | — | — | US | disclosed |
| US-20040204421-A1 | Certain 1,3-disubstituted isoquinoline derivatives | EISAI CO., LTD. | 2004-10-14 | — | — | US | disclosed |
| US-6790844-B2 | MUSCLE RELAXANTS; ANTISEROTONINE AGENT | EISAI CO., LTD (JP) | 2004-09-14 | — | — | US | disclosed |
| US-20020013460-A1 | Condensed pyridine compound | EISAI CO., LTD | 2002-01-31 | — | — | US | disclosed |
| US-6340759-B1 | ANTISPASMODIC AGENTS | EISAI CO., LTD. (JP) | 2002-01-22 | — | — | US | disclosed |
| EP-1123702-A1 | ANALGESICS | Eisai Co., Ltd. (JP) | 2001-08-16 | — | — | EP | disclosed |
| EP-1020445-A1 | FUSED PYRIDINE DERIVATIVES | Eisai Co., Ltd. (JP) | 2000-07-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020013460-A1 | Condensed pyridine compound | MUSK, HTR1A, PAX3 | RAB9A 2421/4885NPC1 4578/4885MAPK1 1599/4885 |
| US-20080027039-A1 | Method for treating a motor neuron disease | SMN1; SMN2, NLN, SLC18A2 | RAB9A 936/4885NPC1 879/4885MAPK1 4465/4885 |
| US-20040204421-A1 | Certain 1,3-disubstituted isoquinoline derivatives | MUSK, HTR1A, RYR1 | RAB9A 2304/4885NPC1 4576/4885MAPK1 1787/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.